PMID- 29623501
OWN - NLM
STAT- MEDLINE
DCOM- 20181113
LR  - 20181114
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
VI  - 50
IP  - 6
DP  - 2018 Jun
TI  - Silymarin and celecoxib ameliorate experimental varicocele-induced pathogenesis: 
      evidences for oxidative stress and inflammation inhibition.
PG  - 1039-1052
LID - 10.1007/s11255-018-1862-5 [doi]
AB  - BACKGROUND: The present study was done to investigate the ameliorative effect of 
      silymarin (SMN) and celecoxib (CEL) on varicocele (VCL)-induced detrimental 
      impact in testicular tissue. METHODS: Mature Wistar rats were divided into 
      control and test groups. Following VCL induction, the animals in test group were 
      subdivided into non-treated VCL-induced, SMN-treated (50 mg/kg, orally), 
      CEL-treated (10 mg/kg) and SMN + CEL-treated groups. Following 60 days, 
      testicular total antioxidant capacity (TAC), malondialdehyde (MDA), nitric oxide 
      (NO), superoxide dismutase (SOD), glutathione peroxidase (GSH-px), total thiol 
      molecules (TTM), mRNA and protein levels of COX2 and mRNA level of iNos were 
      analyzed. Moreover, the germinal cells apoptosis and mRNA damage were examined. 
      RESULTS: Observations revealed that co-administration of SMN and CEL 
      significantly (P < 0.05) up-regulated TAC, SOD, GSH-px and TTM levels and 
      resulted in a remarkable (P < 0.05) reduction in iNos and COX2 expression, NO and 
      MDA contents. The animals in SMN + CEL-treated group exhibited significantly 
      (P < 0.05) lower number of apoptotic cells and cells with mRNA damage per one 
      mm(2). CONCLUSION: The SMN by up-regulating testicular TAC, SOD, GSH-px and TTM 
      levels and the CEL by inhibiting COX2 and iNos expression as well as NO content 
      could fairly ameliorate the VCL-decreased spermatogenesis.
FAU - Mazhari, Sara
AU  - Mazhari S
AD  - Division of Histology and Embryology, Department of Basic Science, Faculty of 
      Veterinary Medicine, Urmia University, P.O. Box: 1177, Urmia, Iran.
FAU - Razi, Mazdak
AU  - Razi M
AUID- ORCID: 0000-0002-4309-4831
AD  - Division of Histology and Embryology, Department of Basic Science, Faculty of 
      Veterinary Medicine, Urmia University, P.O. Box: 1177, Urmia, Iran. 
      mazdak.razi@gmail.com.
FAU - Sadrkhanlou, Rajabali
AU  - Sadrkhanlou R
AD  - Division of Histology and Embryology, Department of Basic Science, Faculty of 
      Veterinary Medicine, Urmia University, P.O. Box: 1177, Urmia, Iran.
LA  - eng
PT  - Journal Article
DEP - 20180405
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - 0 (Antioxidants)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Silymarin)
RN  - 0 (Sulfhydryl Compounds)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.13.39 (Nos2 protein, rat)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism/*therapeutic use
MH  - Apoptosis
MH  - Celecoxib/*therapeutic use
MH  - Cyclooxygenase 2/genetics/metabolism
MH  - Cyclooxygenase 2 Inhibitors/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Glutathione Peroxidase/metabolism
MH  - Inflammation/drug therapy/etiology
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Synthase Type II/genetics
MH  - Oxidative Stress/drug effects
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Silymarin/*therapeutic use
MH  - Sulfhydryl Compounds/metabolism
MH  - Superoxide Dismutase/metabolism
MH  - Testicular Diseases/*drug therapy/etiology/*metabolism/pathology
MH  - Varicocele/*complications
OTO - NOTNLM
OT  - COX2
OT  - Oxidative stress
OT  - Testis
OT  - Varicocele
OT  - iNos
EDAT- 2018/04/07 06:00
MHDA- 2018/11/14 06:00
CRDT- 2018/04/07 06:00
PHST- 2018/01/03 00:00 [received]
PHST- 2018/03/30 00:00 [accepted]
PHST- 2018/04/07 06:00 [pubmed]
PHST- 2018/11/14 06:00 [medline]
PHST- 2018/04/07 06:00 [entrez]
AID - 10.1007/s11255-018-1862-5 [pii]
AID - 10.1007/s11255-018-1862-5 [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2018 Jun;50(6):1039-1052. doi: 10.1007/s11255-018-1862-5. Epub 
      2018 Apr 5.